Research demonstrates AGR2 predicts outcomes in HER2 cancers, indicating its role in overcoming neratinib resistance.
The development of resistance to HER2-targeted drugs is common. Neratinib, an orally delivered cost effective drug is showing great promise for patients with HER2-overexpressing tumours but, unfortunately, for many the development of resistance is inevitable. In this study spanning novel pairs of cell line models and data from patients′ samples, we used a broad range of methodologies including mass-spectrometry-based quantitative proteomics, ectopic gene expression, RT-qPCR, immunoblotting, cytotoxicity, proliferation, invasion, and migration assays. We found loss of anterior gradient protein 2 (AGR2) to be prognostic for poor overall survival for patients with HER2-overexpressing tumours, in contrast to what has been reported for estrogen-positive breast cancer. Additionally, we discovered that loss of AGR2 is not only associated with neratinb-resistance, but that its restoration by ectopic AGR2 expression in neratinib-resistance cells partly restores their drug sensitivity. Furthermore, we established that keys metastatic phenotypic traits acquired with neratinib-resistance were blocked by ectopic AGR2 expression in the cells. Taken together, our results show that AGR2 has potential as a prognostic biomarker for outcome from HER2- overexpressing cancer; a predictive biomarker for resistance/response to neratinib; and a potential therapeutic protein for helping restore sensitivity to neratinib and overcoming aggressive cellular traits associated with cancer metastasis.
No takes yet. Share an insight, caveat, or question.
Pacheco et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: